Completed PHASE2 NCT00482079

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Sponsor: Merck Sharp & Dohme LLC

Conditions Diabetes Mellitus, Type II

Interventions Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks

Updated 7 times since 2017 Last updated: Mar 24, 2017 Started: May 13, 2003 Primary completion: Aug 25, 2004 Completion: Jun 15, 2006

This PHASE2 trial investigates Diabetes Mellitus, Type II and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Apr 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Apr 2017 [monthly]

Completed PHASE2

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.